PCI Pharma Services On Strategy, Innovation And The Future Of CDMOs

The CDMO sector is undergoing a period of rapid transformation, driven by evolving development pipelines, surging demand for injectables, and increasing geopolitical and regulatory complexity. In this Q&A, Chief Commercial Officer Tim Roberts describes how contract development and manufacturing partners are no longer just service providers — they are becoming critical innovation hubs, advancing technology, expanding capacity, and building specialized expertise that biopharma companies depend on more than ever.

Roberts goes on to note the continued rise of biologics and GLP-1 therapies, alongside a renewed focus on regionalized manufacturing and more resilient supply chains. The discussion also underscores the growing importance of deep client collaboration, a strong quality culture, and strategic investment in capabilities such as sterile fill-finish, high-potency oral solid doses, and complex drug-device combinations.

Looking ahead, the next generation of CDMOs will be defined by their agility, depth of specialization, and commitment to patient-centric design. This preview highlights the major forces shaping the conversation, while leaving the full range of insights to be explored in the complete Q&A.